4890-15-7 Usage
Derived from
Phthalic acid
Usage
Plasticizer, solvent in perfumes, dyes, and insecticides
Endocrine disruptor
Yes, can interfere with the body's hormonal system
Health effects
Reproductive and developmental toxicity
Environmental impact
Potentially harmful, should be handled and disposed of carefully
Physical state
Liquid
Solubility
Soluble in water and organic solvents
Molecular weight
210.18 g/mol
Appearance
Colorless to slightly yellowish oily liquid
Odor
Mild, ester-like
Boiling point
Approximately 356°C
Melting point
Less than 0°C
Density
1.18 g/cm3
Viscosity
Low to moderate
Flash point
171°C (closed cup)
Vapor pressure
Low
Stability
Stable under normal conditions, may decompose upon heating or exposure to light
Reactivity
Reacts with strong oxidizing agents, acids, and bases
Regulatory status
Restricted or banned in some countries due to health and environmental concerns
EINECS number
224-473-2
Hazard statement
H301 (Toxic if swallowed), H361d (Suspected of damaging fertility), H361f (Suspected of causing developmental toxicity)
Check Digit Verification of cas no
The CAS Registry Mumber 4890-15-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,8,9 and 0 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 4890-15:
(6*4)+(5*8)+(4*9)+(3*0)+(2*1)+(1*5)=107
107 % 10 = 7
So 4890-15-7 is a valid CAS Registry Number.
4890-15-7Relevant articles and documents
Design and synthesis of tricyclic terpenoid derivatives as novel PTP1B inhibitors with improved pharmacological property and in vivo antihyperglycaemic efficacy
Chen, Feng,Chen, Jiabao,Gao, Cheng,Li, Junyan,Liu, Siyan,Qian, Shan,Wang, Zhouyu,Yang, Lingling,Zhang, Yuanyuan
, p. 152 - 164 (2019/11/25)
Overexpression of protein tyrosine phosphatase 1B (PTP1B) induces insulin resistance in various basic and clinical research. In our previous work, a synthetic oleanolic acid (OA) derivative C10a with PTP1B inhibitory activity has been reported. However, C10a has some pharmacological defects and cytotoxicity. Herein, a structure-based drug design approach was used based on the structure of C10a to elaborate the smaller tricyclic core. A series of tricyclic derivatives were synthesised and the compounds 15, 28 and 34 exhibited the most PTP1B enzymatic inhibitory potency. In the insulin-resistant human hepatoma HepG2 cells, compound 25 with the moderate PTP1B inhibition and preferable pharmaceutical properties can significantly increase insulin-stimulated glucose uptake and showed the insulin resistance ameliorating effect. Moreover, 25 showed the improved in vivo antihyperglycaemic potential in the nicotinamide–streptozotocin-induced T2D. Our study demonstrated that these tricyclic derivatives with improved molecular architectures and antihyperglycaemic activity could be developed in the treatment of T2D.
